Adherence

Adherence features

• 

  The generic generation

  In the next few years, some of the most widely used HIV drugs will come off patent in the UK. Gus Cairns asks: what are the...

  From:  HIV treatment update

• 

  Adherence and retention in HIV care in resource-limited settings

  Recent research on adherence to HIV treatment and retention in HIV care in resource-limited settings....

  From:  HIV & AIDS treatment in practice

• 

  Once-a-day pills and other sticky problems

  Less-than-perfect adherence to a once-a-day HIV treatment carries five times more risk of treatment failure than imperfect adherence to a twice-a-day regimen. That’s one of the surprising things...

  From:  HIV treatment update

• 

  In for the long haul

  With modern treatment, people with HIV can expect to live for decades and decades. But is this sustainable? How realistic is it to expect the drugs to...

  From:  HIV treatment update

• 

  Using mobile phones in HIV care and prevention

  This issues provides an over view of the growing role of mobile technology in HIV care and prevention in resource-poor settings. ...

  From:  HIV & AIDS treatment in practice

• 

  Adherence and long-term treatment success

  Taking your HIV medication correctly (the technical term for this is adherence) is the single most important thing you can do to make sure your HIV treatment...

  From:  HIV treatment update

• 

  How to deliver good adherence support: lessons from round the world

  A review of the barriers to good adherence to antiretroviral treatment in resource-limited settings, and the evidence of which interventions most successfully support adherence....

  From:  HIV & AIDS treatment in practice

• 

  A follow-up on follow-up: shifting to a community-based response to improve retention in care

  Further discussion on issues relating to retention in HIV care in low-income settings, with a focus on community-based care and task-shifting as potential solutions to...

  From:  HIV & AIDS treatment in practice

Adherence in your own words

• 

  Starting treatment wasn't as scary as I thought!

  I started learning about HIV treatment soon after I was first diagnosed. I had ‘the chat’ with someone, after I got my results – I...

  From:In your own words

• 

  Getting into the habit

  I try to take my HIV drugs at the same time every day, just before bed. I used to set an alarm on my mobile,...

  From:In your own words

• 

  Holiday hassles and HRT

  A much-needed holiday. Tickets, passports, driving licence – all go in my hand luggage. I leave the toiletry bag out till the last minute. I...

  From:In your own words

• 

  The Ikea approach

  I’ve no doubt that the main reason that I’m alive and well after 15 years of living with HIV is because combination therapy became available...

  From:In your own words

• 

  'I just take the tablets and get on with my life'

  I was diagnosed HIV-positive in 1997. I'm now 65. It was a bit of a shock. It could never happen to me, after all. I...

  From:In your own words

• 

  Jewelled friends

  I have a pretty little carved wooden pill box which I’d bought in Eureka, California. It holds my tablet set for the evening if I’m...

  From:In your own words

• 

  Time will tell

  I was devastated when I got the news that I was HIV-positive. But I was lucky to have such a supportive GP. It was thanks...

  From:In your own words

Adherence news from aidsmap

• Combining tenofovir with FTC or 3TC boosts chances of HBV suppression for people co-infected with HIV

  A study involving people co-infected with HIV and hepatitis B virus (HBV) shows that antiretroviral therapy that combines tenofovir with FTC or 3TC has the best chance of suppressing HBV replication to undetectable levels. The research is published in ...

  19 February 2013 | Michael Carter

• Australian researchers project that many HIV-positive people will run out of treatment options

  Running out of antiretroviral treatment options may severely curtail the life expectancy of people with HIV in resource-rich countries, according to Australian research published in the online edition of AIDS. The research expands upon a study ...

  22 January 2013 | Michael Carter

• Any reduction in viral load has immunologic benefits for people with HIV who have triple-class treatment failure

  HIV therapy that achieves even modest reductions in viral load can have profound immunological benefits for people with triple-class treatment failure, European investigators report in the online edition of the Journal of Infectious Diseases. “There is close to a linear ...

  08 January 2013 | Michael Carter

• Neurocognitive impairment results in poorer adherence to HIV therapy

  Neurocognitive impairment and problems with memory are associated with poorer adherence to antiretroviral therapy, investigators from the United States report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The study also showed that better adherence ...

  07 January 2013 | Michael Carter

• Adherence to hepatitis C treatment: unravelling the complexities

  Successful adherence to hepatitis C treatment may require physicians and care teams to address a wide range of factors, according to research from the United States and Germany presented at The Liver Meeting 2012, the 63rd annual meeting of the ...

  13 December 2012 | Rob Camp

• Out-of-clinic adherence club for delivery of ARVs shows better retention than standard of care

  An out-of-clinic model of HIV treatment delivery in South Africa has shown superior results to the standard in-clinic delivery of antiretrovirals (ARVs), according to results of an evaluation presented by Dr Gilles Van Cutsem at the Southern African ...

  03 December 2012 | Lesley Odendal

• Dosing frequency and number of pills don't affect HIV treatment outcomes

  Levels of adherence to modern HIV treatment are unaffected by dosing frequency or number of daily pills, Italian investigators report in HIV Medicine. However, people who were taking larger numbers of pills reported poorer health. The investigators suggest this is ...

  04 October 2012 | Michael Carter

• Higher levels of adherence to hepatitis C therapy improve treatment outcomes in people with hepatitis C and HIV

  Higher levels of adherence to pegylated interferon and ribavirin are associated with better hepatitis C treatment responses in people with HIV and hepatitis C co-infection, US investigators report in AIDS and Behavior. Adherence to both anti-hepatitis C drugs fell during ...

  03 October 2012 | Michael Carter

• Global evidence of lower adherence to ARVs after giving birth

  Antiretroviral therapy (ART) adherence levels among pregnant women with HIV, in both high- and low-income countries, during pregnancy and especially after giving birth are significantly below what is recommended for viral suppression and prevention of drug resistance, according to a ...

  25 September 2012 | Carole Leach-Lemens

• Near-perfect adherence needed to suppress cell-associated HIV

  Complete adherence to antiretroviral therapy is needed to ensure suppression of cell-associated HIV, investigators from the Netherlands report in the online edition of the Journal of Infectious Diseases. A total of 40 people taking long-term HIV therapy were included ...

  05 September 2012 | Michael Carter

More news

Adherence news selected from other sources

• Over 2,000 People Have Stopped HIV Meds for Prayer in Ghana

  A total of 2,248 people with HIV/AIDS on antiretroviral treatment in Ghana have stopped taking their medications to seek help at prayer camps and from traditional healers.

  15 March 2013 | Poz magazine news

• CROI 2013: The VOICE Results—A Social Scientist’s Perspective

  To social scientist Judith D. Auerbach, PhD, a consultant to the NIH Office of AIDS Research and San Francisco AIDS Foundation, the VOICE results raise a number of questions—but not the ones you might think.

  06 March 2013 | BETA blog

• Falling Through the Cracks

  We can strengthen two of the weakest links in the U.S. health care chain for people with HIV/AIDS—linking people to care and retaining them in care—but doing so requires a collective approach.

  05 March 2013 | Poz

• Antiretroviral Drugs Sold for Food in Kenya’s Slums

  Impoverished Kenyans living with HIV/AIDs are sometimes selling their antiretroviral drugs to buy food for themselves and their families. Medical professionals believe there has been a slight growth in the trend, saying that people are simply trying to survive.

  05 March 2013 | Voice of America

• Statements on the VOICE results

  Comments on the disappointing vaginal microbicide and PrEP results from AVAC, the Gates Foundation, the NIH, and others.

  05 March 2013 | AVAC

• Counseling Helps HIV Patients Stick to Tx

  (MedPage Today) -- HIV patients receiving a year-long counseling program on problem solving showed better adherence to drug therapy in a randomized study, researchers said.

  27 February 2013 | MedPage Today HIV/AIDS

• Uzbekistan Short of HIV Drugs

  A shortage of retroviral medicines used to treat HIV/AIDS in Uzbekistan is being put down to the government’s policy of understating national infection rates, and hence the amount of drugs it needs to buy.

  31 January 2013 | Institute for War and Peace Reporting

• Personalized plans to address barriers to HIV drug adherence boost chances of successful therapy

  HIV patients who participated in an intervention that helped them identify barriers to taking their drugs properly and develop customized coping strategies took a significantly greater amount of their prescribed doses than those receiving standard care, according to a new study.

  30 January 2013 | Science Daily

• European Commission Approves PREZISTA® (Darunavir) 800mg Tablet Once A Day

  Janssen R&D Ireland has announced that the European Commission (EC) has approved a new PREZISTA(R) (darunavir) 800mg tablet allowing people living with HIV to take one darunavir tablet once a day.

  18 January 2013 | HIV / AIDS News From Medical News Today

• Reaction to BBC reporting on generic ARVs

  Yesterday the BBC issued a misleading news report on the efficacy of generic antiretroviral drugs (ARVs) suggesting that generic ARVs are less efficacious than branded alternatives. The report, based upon a study led by Massachusetts General Hospital (MGH) and Weill Cornell Medical College investigators, fails to separate the issues of ‘treatment efficacy’ and ‘adherence’ leading to distorted and alarmist conclusions.

  17 January 2013 | Stop AIDS Campaign

More news